Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction

Faraz S. Ahmad; Yuan Luo; Ramsey M. Wehbe; James D. Thomas; Sanjiv J. Shah

doi:10.1016/j.hfc.2021.12.002

Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction

Faraz S. Ahmad, Yuan Luo, Ramsey M. Wehbe, James D. Thomas, Sanjiv J. Shah^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	287-300
Number of pages	14
Journal	Heart Failure Clinics
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.hfc.2021.12.002
State	Published - Apr 2022

Funding

Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health /National Heart, Lung , and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation . The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association. F.A. receives consulting fees from Amgen, Pfizer, and Livongo Teladoc outside of this work. S.J.S. has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.T. receives consulting fees from Edwards, Abbott, GE, and Caption Health and reports spouse employment with Caption Health.Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation. The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association.

Keywords

Artificial intelligence
Deep learning
Heart failure
Machine learning
Natural language processing

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2021.12.002

Cite this

@article{213ed9f86c5d48a09629c113e6460a08,

title = "Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction",

keywords = "Artificial intelligence, Deep learning, Heart failure, Machine learning, Natural language processing",

author = "Ahmad, {Faraz S.} and Yuan Luo and Wehbe, {Ramsey M.} and Thomas, {James D.} and Shah, {Sanjiv J.}",

note = "Funding Information: Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health /National Heart, Lung , and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation . The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association. Funding Information: F.A. receives consulting fees from Amgen, Pfizer, and Livongo Teladoc outside of this work. S.J.S. has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion , AstraZeneca , Corvia , Novartis , and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.T. receives consulting fees from Edwards, Abbott, GE, and Caption Health and reports spouse employment with Caption Health. Funding Information: F.A. receives consulting fees from Amgen, Pfizer, and Livongo Teladoc outside of this work. S.J.S. has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.T. receives consulting fees from Edwards, Abbott, GE, and Caption Health and reports spouse employment with Caption Health.Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation. The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association.",

year = "2022",

month = apr,

doi = "10.1016/j.hfc.2021.12.002",

language = "English (US)",

volume = "18",

pages = "287--300",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction

AU - Ahmad, Faraz S.

AU - Luo, Yuan

AU - Wehbe, Ramsey M.

AU - Thomas, James D.

AU - Shah, Sanjiv J.

N1 - Funding Information: Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health /National Heart, Lung , and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation . The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association. Funding Information: F.A. receives consulting fees from Amgen, Pfizer, and Livongo Teladoc outside of this work. S.J.S. has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion , AstraZeneca , Corvia , Novartis , and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.T. receives consulting fees from Edwards, Abbott, GE, and Caption Health and reports spouse employment with Caption Health. Funding Information: F.A. receives consulting fees from Amgen, Pfizer, and Livongo Teladoc outside of this work. S.J.S. has received research grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, R01 HL149423), Actelion, AstraZeneca, Corvia, Novartis, and Pfizer and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics. J.T. receives consulting fees from Edwards, Abbott, GE, and Caption Health and reports spouse employment with Caption Health.Dr Ahmad was supported by grants from the Agency for Healthcare Research and Quality (K12HS026385), National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL155970), and the American Heart Association (AHA number 856917). Dr Luo was supported by grants from National Institutes of Health (U01TR003528, 1R01LM013337). Dr Thomas was supported by a grant from the Irene D. Pritzker Foundation. The statements presented in this work are solely the responsibility of the author(s) and do not necessarily represent the official views of the Patient-Centered Outcomes Research Institute (PCORI), the PCORI Board of Governors or Methodology Committee, the Agency for Healthcare Research and Quality, the National Institutes of Health, or the American Heart Association.

PY - 2022/4

Y1 - 2022/4

KW - Artificial intelligence

KW - Deep learning

KW - Heart failure

KW - Machine learning

KW - Natural language processing

UR - http://www.scopus.com/inward/record.url?scp=85125705723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125705723&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2021.12.002

DO - 10.1016/j.hfc.2021.12.002

M3 - Review article

C2 - 35341541

AN - SCOPUS:85125705723

SN - 1551-7136

VL - 18

SP - 287

EP - 300

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 2

ER -

Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this